Project Grant K99HL175030
Award Date
8/1/25
Completion Date
7/31/27
Dollars Obligated
$129K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
This $1,102,500 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will support research at the University of California, Los Angeles (UCLA) to address persistent problems in the field of intravascular triglyceride metabolism. The key focus areas include: Identifying sequences in apolipoprotein A5 (apoA5) that are important for suppressing the activity of the ANGPTL3/8 complex, and using that knowledge...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Federal Grant Program CFDA 93.837 - Cardiovascular Diseases Research, will support research to define cellular pathways that regulate lipid flux and elucidate their impact on cardiovascular disease. The $773,259 award, with a project period from December 2024 to November 2028, will enable the University of California, Los Angeles (UCLA) to: 1) Identify novel cholesterol-responsive proteins in the...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $699,133 in funding to the University of California, Los Angeles (UCLA) to conduct research on the epigenetic regulation of heart failure with preserved ejection fraction (HFPEF). The key goals are to reveal molecular insights into the actions of SGLT2 inhibitor and GLP1 agonist drugs across multiple organs, identify novel...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $2,352,138 Project Grant under CFDA 93.837 - Cardiovascular Diseases Research to the Rector & Visitors of the University of Virginia. The grant aims to model and experimentally validate cell-specific signaling networks involving the low-density lipoprotein receptor-related protein 1 (LRP1) in acute myocardial infarction (AMI). The research will focus on understanding how early cardiomyocyte LRP1 signaling enhances cell...
This Project Grant awarded by the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $147,486 to Baylor College of Medicine to conduct research aimed at improving genetic testing for cardiovascular disease (CVD). The key objectives are to: Study the genetics of CVD and lipoprotein(a) (Lp(a)) across diverse and mixed-ancestry populations using novel tools that appropriately evaluate ancestry. This includes evaluating the role of linkage...
This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $787,267 to Yale University from January 1, 2025 to November 30, 2028 to conduct research aimed at determining whether genetic deletion of the DHCR24 enzyme in macrophages or hepatocytes can attenuate the progression of atherosclerosis. The project will exploit novel animal models and cutting-edge genomic and metabolomic technologies to evaluate the therapeutic...
This $506,984 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), aims to investigate the role of the LRP1 gene in the development of congenital heart disease (CHD). The primary objectives are to: Examine the deployment and migration of cardiac neural crest cells (CNCCs) and their dependence on LRP1 using in vitro and in vivo cell lineage fate mapping analysis. Investigate the cellular and molecular...
This $110,959 federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to understand the mechanisms driving the transition of lipofibroblasts to myofibroblasts in systemic sclerosis, a rare autoimmune fibrosing disease with high mortality. The research aims to define the role of the genes PER3 and CD36 in regulating the lipofibroblast to myofibroblast transition, which is a key driver...
The federal Project Grant award "USING DEFECTIVE LIPOYLATION AS A WINDOW INTO CARDIAC FUEL CONSUMPTION AND FAILURE" is funded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The $154,568 award, spanning Dec 2024 to Aug 2027, supports research to characterize the cardiac metabolic and functional consequences of lipoyl deficiency at the University of Texas Southwestern Medical Center. The central hypothesis is...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $771,750 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of California, Los Angeles (UCLA) to investigate the role of macrophages in regulating cardiac muscle metabolism after myocardial infarction. The project aims to shed novel insights into how macrophages recruited to the infarcted heart disrupt cardiac muscle metabolism and lead to decreased NAD pools, which play a critical...